Ambrx Biopharma Inc.
AMAMNYSEHealthcare
$28.00
+$0.02(+0.07%)
Market Cap$1.8B
P/E Ratio—
52W High$28.15
52W Low$6.55
Ambrx Biopharma Inc.（AMAM）· 资产负债表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · AMAM · 截至 2026-06-10
财务报表
Total Assets · Total Liabilities · Equity
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|
| Assets | ||||
| Cash & ST Investments | $84.48M | $170.06M | $90.46M | $15.49M |
| Net Receivables | $2.05M | $1.34M | $0.98M | $1.39M |
| Inventory | $3.73M | $5.17M | $1.44M | $1.13M |
| Total Current Assets | $90.58M | $176.81M | $93.08M | $18.16M |
| PP&E Net | $14.01M | $15.72M | $3.49M | $4.97M |
| Goodwill | $0.00M | $0.00M | $0.00M | $0.00M |
| Intangible Assets | $25.25M | $35.96M | $36.83M | $38.28M |
| Total Assets | $146.98M | $229.02M | $134.02M | $61.73M |
| Liabilities | ||||
| Short-Term Debt | $1.73M | $0.92M | $1.59M | $1.45M |
| Accounts Payable | $3.21M | $5.27M | $2.82M | $5.39M |
| Total Current Liabilities | $16.66M | $24.58M | $13.26M | $14.94M |
| Long-Term Debt | $10.24M | $12.21M | $1.60M | $3.19M |
| Total Liabilities | $29.13M | $39.05M | $272.17M | $25.74M |
| Stockholders Equity | ||||
| Retained Earnings | ($291.63M) | ($213.63M) | ($145.55M) | ($129.01M) |
| Total Stockholders Equity | $117.85M | $189.97M | ($139.43M) | $33.42M |
| Total Liab & Equity(computed) | $146.98M | $229.02M | $132.73M | $59.16M |
| Debt Summary | ||||
| Total Debt | $11.98M | $13.13M | $3.19M | $4.65M |
| Net Debt | ($43.63M) | ($156.94M) | ($87.27M) | ($10.85M) |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · M
深入了解Ambrx Biopharma Inc.
关于Ambrx Biopharma Inc.（AMAM）资产负债表
Ambrx Biopharma Inc.总资产$0.15B，现金及短期投资$0.08B，总负债$0.03B，总债务$0.01B，股东权益$0.12B。
常见问题
AMAM · 4 问Ambrx Biopharma Inc.总债务$0.01B，净债务($0.04B)。
AMAM total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10